Skip to content

Add your earlier progress to your account?

From before you signed in, this browser has:

Which plan do you want to keep?

You answered the plan questions before you signed in, and those answers don't match the plan saved on your account.

SettingSaved planNew answers

Study progress is waiting to be saved

Warm and drug-induced immune hemolysis

17 min

Skills you'll build2 skills
  • Exclude underlying alloantibodies and select antigen-matched units for a warm autoantibody
  • Tell drug-induced immune hemolysis from a delayed hemolytic reaction after transfusion

At the bench: Use the antibody workup to select suitable donor units · Perform and document the laboratory workup of a transfusion reaction

Try first

Try first

A patient with warm autoimmune hemolytic anemia has a panreactive antibody screen and a reactive autocontrol. She received 2 red-cell units 3 weeks ago. How does the laboratory detect an alloantibody masked by the autoantibody?

Keep going to see the reasoning.

Keep going to see the reasoning.

Right. Keep going to follow the reasoning.

Keep going to see the reasoning.

Get the idea

Use the explanation to check your first decision.

Warm autoantibody workup

In warm autoimmune hemolytic anemia (WAIHA), an IgG autoantibody reacts near 37 °C with an antigen almost everyone carries. The DAT is usually positive for IgG, with or without C3d.1,2 The antibody screen, the panel, the autocontrol and every donor unit can react at the antiglobulin phase. That broad reactivity can mask an alloantibody formed after transfusion or pregnancy.1,3

Adsorption removes the autoantibody so that alloantibodies can be detected:1,3

  1. Autologous adsorption uses the patient's own cells. It needs no transfusion in the preceding 3 months and enough patient cells.
  2. Allogeneic adsorption uses donor cells of selected phenotypes. A reference laboratory can do this work.

Units are ABO-compatible and lack the antigens of every current and historical clinically significant alloantibody. The patient's phenotype or genotype guides Rh and K matching. The autoantibody may still react with every unit. "Least incompatible" is an obsolete term, because crossmatch grades against an autoantibody do not identify a safer unit. The release record documents this limitation of the testing.3

Drug-induced hemolysis and delayed hemolytic reactions

Drug-induced immune hemolysis is rare. A drug-dependent antibody may react only when the drug is in the test system, so the plasma screen and the eluate can be nonreactive with ordinary reagent cells.4 A recent transfusion is another possible cause. An anamnestic alloantibody rises 2 to 14 days after re-exposure and coats the donor cells in a delayed hemolytic transfusion reaction.1

FindingDrug-dependent antibodyDelayed hemolytic reaction
HistoryHemolysis follows a drug exposureA transfusion in the previous 2 weeks
EluateNonreactive with untreated cells, or reactive only with the drug addedA specific alloantibody, such as anti-Jka
Confirming findingReactivity with the drug present and none without itThe patient lacks the antigen, and the transfused units carry it

Timing alone cannot distinguish the two. The laboratory refers drug-dependent testing when the pattern fits and keeps the transfusion investigation open until an alloantibody is excluded.3,4

Follow the bench demonstration

Sources for this step
References
  1. Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026.
  2. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi:10.1016/j.blre.2019.100648
  3. Johnson ST, Puca KE. Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies. Hematology Am Soc Hematol Educ Program. 2022;2022(1):96-104. doi:10.1182/hematology.2022000406
  4. Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia. Immunohematology. 2014;30(2):85-94. doi:10.21307/immunohematology-2019-102

Watch one

Read each decision and its explanation.

Samuel Bubb, 67, MRN 7730562, received 2 red-cell units 6 days ago after surgery. Piperacillin-tazobactam was started 3 days ago.

The plasma panel reacts 1+ at the antiglobulin phase with Jk(a+) cells only. An acid eluate reacts 2+ with Jk(a+) cells only.

What explains the hemolysis?

TestResultPreviousReference intervalFlag
Hemoglobin7.1 g/dL Low3 days ago: 9.6 g/dL9.6 g/dL3 days ago13.2–16.6 g/dL13.2–16.6Low
Total bilirubin3.0 mg/dL High3 days ago: 0.9 mg/dL0.9 mg/dL3 days ago0.1–1.2 mg/dL0.1–1.2High
Lactate dehydrogenase610 U/L High3 days ago: 230 U/L230 U/L3 days ago140–280 U/L140–280High
Haptoglobin<10 mg/dL Low3 days ago: 110 mg/dL110 mg/dL3 days ago30–200 mg/dL30–200Low
DAT, anti-IgGReactive, 2+NonreactiveNonreactive
DAT, anti-C3dReactive, 1+NonreactiveNonreactive

Specimen: H 4, L 9, I 3. EDTA and clotted specimens collected before the next dose

  1. Establish hemolysis. Hemoglobin fell from 9.6 to 7.1 g/dL with raised bilirubin and lactate dehydrogenase and haptoglobin below 10 mg/dL.

    Hemolysis must be established before its cause is investigated.

  2. Review the exposures. The transfusion 6 days ago fits an anamnestic alloantibody, and the drug started 3 days ago fits a drug-dependent antibody.

    Timing suggests both causes and confirms neither.

  3. Read the DAT. IgG and C3d coat the cells, which shows sensitization without identifying its cause.

    IgG with some C3d occurs in both.

  4. Read the eluate. It reacts only with Jk(a+) cells, the pattern of anti-Jka.

    Specific eluate reactivity points to an alloantibody coating transfused cells.

  5. Confirm. His retained pretransfusion specimen types Jk(a−), and the segments of both units type Jk(a+).

    The antibody explains the hemolysis only if his cells lack the antigen and the donor cells carry it.

  6. Report a delayed hemolytic transfusion reaction from anti-Jka. Add it to his antibody history and select Jk(a−), antiglobulin-crossmatched units from now on.

    The alloantibody determines his future unit requirements.

A delayed hemolytic transfusion reaction from anti-Jka. The eluate's specificity, his Jk(a−) type and the Jk(a+) donor units explain the hemolysis, so no drug investigation is needed unless the hemolysis stays unexplained.

Practice this skill

Your turn

Problem 1 of 3 · Hints available

A patient with warm autoimmune hemolytic anemia and two previous pregnancies has panreactive indirect antiglobulin test (IAT) results and a reactive autocontrol. What must the workup still establish before red cells are selected?

Incorrect. A panreactive eluate supports the warm autoantibody that the plasma results already suggest. It does not show whether a separate alloantibody is present in the plasma.

Correct. Pregnancy can stimulate alloantibodies, and a broadly reactive autoantibody can hide them. The antibody history, allogeneic or autologous adsorption or reference testing, and the patient's antigen profile address that risk.

Incorrect. The titer describes only the autoantibody. Unit safety depends on finding or excluding alloantibodies.

Hint
  1. Pregnancy and transfusion both expose a person to red-cell antigens they lack.
  2. Ask what a broadly reactive autoantibody does to the reactions of any other antibody in the same plasma.

Review Immunohematologic evaluation

Problem 2 of 3 · Hints available

During ceftriaxone treatment, a patient has laboratory evidence of hemolysis and a direct antiglobulin test (DAT) positive for IgG and C3d. The plasma screen and an acid eluate are nonreactive with untreated reagent cells. How is the nonreactive eluate interpreted?

Incorrect. The eluate was tested only against untreated cells. The coating that the DAT detected, together with the hemolysis, still needs an explanation.

Incorrect. A typical warm autoantibody gives a broadly reactive eluate and plasma, and these nonreactive results argue against it.

Correct. Ordinary reagent cells carry no drug, so an antibody that needs the drug in the test system can leave routine tests nonreactive. Reference testing with and without ceftriaxone shows whether the reactivity depends on the drug.

Hint
  1. Ask what ordinary reagent cells lack that a drug-dependent antibody needs.
  2. Think about what a test system without the drug can show.

Review Laboratory investigation

Problem 3 of 3 · On your own

A 45-year-old woman who has never been transfused or pregnant develops abrupt intravascular hemolysis within an hour of starting a second course of ceftriaxone. Her DAT is reactive for C3d only. The plasma screen and an acid eluate are nonreactive. Which explanation fits, and what follows?

Ordinary reagent cells carry no drug, so routine tests can stay nonreactive. Reference testing with and without ceftriaxone shows whether her antibody needs the drug.

She has never been transfused or pregnant. No earlier exposure could have primed an alloantibody.

A warm autoantibody reacts broadly in plasma and eluate. Both are nonreactive here.

Her abrupt hemolysis makes the DAT meaningful. The coating and the destruction both need an explanation.

Review Laboratory investigation

Use it

Read the case evidence, then make each decision. The step is complete without it.

  • Deborah Frost, 52, MRN 4906733, has warm autoimmune hemolytic anemia. Her hemoglobin is 6.4 g/dL, and her physician orders 2 red-cell units.
  • She has had three pregnancies and has never been transfused. She has no antibody history.
  • Her DAT is IgG 3+ and C3d 1+. Every screening and panel cell reacts 2+ at the antiglobulin phase, and her autocontrol reacts 2+.
  • Her red-cell genotype predicts D+ C+ E− c− e+ and K−.
Decision 1 of 2

How does the laboratory look for an alloantibody?

Her three pregnancies exposed her to red-cell antigens from each baby's father. The autoantibody could mask an alloantibody from those pregnancies.

She has never been transfused, so her cells carry only her own antigens. Adsorbing with them removes the autoantibody and leaves any alloantibody in the plasma.

An eluate shows what coats her own cells, which is the autoantibody. An alloantibody to an antigen she lacks stays in the plasma.

Review Immunohematologic evaluation

Decision 2 of 2

The adsorbed plasma reacts 2+ at the antiglobulin phase with E-positive cells only, and anti-E is identified. Every E-negative unit still reacts 1+ to 2+ in the crossmatch. Which units are issued?

The units lack E, and matching her c−, K− type lowers the chance of new alloantibodies. The autoantibody explains the remaining reactivity, and the release record states that limit.

Crossmatch grades against an autoantibody do not identify a safer unit. An E-positive unit could be destroyed by her anti-E.

Ranked broadly reactive units by the weakest reaction

When an autoantibody reacts with every unit, the crossmatch grades give no information about an underlying alloantibody, and "least incompatible" is an obsolete term. Picking the weakest-reacting unit can issue red cells that carry the antigen for a masked alloantibody. Units are selected after underlying alloantibodies are excluded, and they are antigen-matched.

The autoantibody may react with every unit indefinitely. Waiting delays needed red cells without adding safety.

Review Immunohematologic evaluation

She had never been transfused, so her own cells could be used for autologous adsorption, which revealed the anti-E masked by the autoantibody. Units were selected by antigen type, and the release record documented the crossmatch reactivity.

For reference

Sources checked